Anti-signal recognition particle-positive juvenile polymyositis successfully treated with rituximab

J Rheumatol. 2012 Jul;39(7):1483-5. doi: 10.3899/jrheum.111592.
No abstract available

Publication types

  • Case Reports
  • Letter

MeSH terms

  • Antibodies, Monoclonal, Murine-Derived / therapeutic use*
  • Autoantibodies / blood*
  • Azathioprine / therapeutic use
  • Child
  • Drug Therapy, Combination
  • Female
  • Humans
  • Immunoglobulins, Intravenous / therapeutic use
  • Immunosuppressive Agents / therapeutic use*
  • Isoxazoles / therapeutic use
  • Leflunomide
  • Muscle, Skeletal / drug effects
  • Muscle, Skeletal / enzymology
  • Polymyositis / drug therapy*
  • Polymyositis / pathology
  • Rituximab
  • Signal Recognition Particle / immunology*
  • Treatment Outcome

Substances

  • Antibodies, Monoclonal, Murine-Derived
  • Autoantibodies
  • Immunoglobulins, Intravenous
  • Immunosuppressive Agents
  • Isoxazoles
  • Signal Recognition Particle
  • Rituximab
  • Leflunomide
  • Azathioprine